The effects of 5α-reductase inhibitors on the natural history, detection and grading of prostate cancer: Current state of knowledge

Journal of Urology

Volumn 174, Issue 6, 2005, Pages 2098-2104

  Andriole, Gerald ^a,g   Bostwick, David ^b   Civantos, Francisco ^c   Epstein, Jonathan ^d   Lucia, M Scott ^e   McConnell, John ^f   Roehrborn, Claus G ^f  

^a WASHINGTON UNIVERSITY   (United States)

^b BOSTWICK LABORATORIES   (United States)

^c Cedars Medical Center Miami   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoprevention; Cholestenone 5 alpha reductase; Prostate; Prostatic neoplasms

Indexed keywords

4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; ACID PHOSPHATASE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; DOXAZOSIN; DUTASTERIDE; EPRISTERIDE; FINASTERIDE; FLUTAMIDE; ISOENZYME; LEUPRORELIN; LUTEINIZING HORMONE; N [2,2,2 TRIFLUORO 1 PHENYL 1 (TRIFLUOROMETHYL)ETHYL] 3 OXO 4 AZA 5ALPHA ANDROST 1 ENE 17BETA CARBOXAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TUROSTERIDE; ANTINEOPLASTIC AGENT; CHOLESTENONE 5ALPHA REDUCTASE; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DIAGNOSTIC ERROR; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; ENZYME SPECIFICITY; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL LITERATURE; MEDLINE; NONHUMAN; ORGAN SIZE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; PROSTATECTOMY; REVIEW; RISK REDUCTION; SAMPLING; TISSUE STRUCTURE; CANCER STAGING; DRUG ANTAGONISM; MALE; PATHOLOGY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; CHOLESTENONE 5 ALPHA-REDUCTASE; CLINICAL TRIALS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 27744492261     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000181216.71605.38     Document Type: Review

References (52)

1. Cabot, A.: The question of castration for enlarged prostate. Ann Surg, 24: 265, 1896
2. White, J. W.: The present position of the surgery of the hypertrophied prostate. Ann Surg, 18: 152, 1893
3. Huggins, C. and Hodges, C. V.: Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res, 1: 293, 1941
4. Huggins, C., Stevens, R. and Hodges, C.: Studies on prostatic carcinoma: II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg, 43: 209, 1941
5. Denis, L. and Murphy, G. P.: Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer, suppl., 72: 3888, 1993
6. Kyprianou, K., English, H. F. and Isaacs, J. T.: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res, 50: 3748, 1990
7. Isaacs, J. T.: Antagonistic effect of androgens on prostatic cell death. Prostate, 5: 545, 1984
8. Bruckheimer, E. M. and Kyprianou, N.: Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res, 301: 153, 2000
9. Wright, A. S., Thomas, L. N., Douglas, R. C., Lazier, C. B. and Rittmaster, R. S.: Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest, 98: 2558, 1996
10. Kokontis, J. M. and Liao, S.: Molecular action of androgen in the normal and neoplastic prostate. Vitam Horm, 55: 219, 1999
11. Harris, K. A. and Small, E. J.: Hormonal treatment for prostate cancer. Expert Opin Investig Drugs, 10: 493, 2001
12. McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L. et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med, 338: 557, 1998
13. Gormley, G. J., Brawley, O. and Thompson, L: The potential application of finasteride for chemoprevention of prostate cancer. Ann N Y Acad Sci, 768: 163, 1995
14. Thompson, I. M., Feigl, P. and Coltman, C.: Chemoprevention of prostate cancer with finasteride. In: Important Advances in Oncology. Edited by V. T. DeVita, S. Hellman and S. A. Rosenberg. Philadelphia: J. B. Lippincott Company, p. 57, 1995
15. Thompson, I. M., Coltman, C. A., Jr. and Crowley, J.: Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate, 33: 217, 1997
16. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G. et al: The influence of finasteride in the development of prostate cancer. N Engl J Med, 349: 215, 2003
17. Span, P. N., Völler, M. C. W., Smals, A. G. H., Sweep, F. G. J., Schalken, J. A., Feneley, M. R. et al: Selectivity of finasteride as an in vivo inhibitor of 5α-reductase isozyme enzymatic activity in the human prostate. J Urol, 161: 332, 1999
18. Brooks, J. R., Berman, C., Nguyen, H., Prahalada, S., Primka, R. L., Rasmusson, G. H. et al: Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate, 18: 215, 1991
19. Bologna, M., Muzi, P., Biordi, L., Festuccia, C. and Vicentini, C.: Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology, 45: 282, 1995
20. Iehle, C., Delos, S., Guirou, O., Tate, R., Raynaud, J. P. and Martin, P. M.: Human prostatic steroid 5 alpha-reductase isoforms-a comparative study of selective inhibitors. J Steroid Biochem Mol Biol, 54: 273, 1995
21. di Salle, E., Giudici, D., Radice, A., Zaccheo, T., Ornati, G., Nesi, M. et al: PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor. J Steroid Biochem Mol Biol, 64: 179, 1998
22. Zaccheo, T., Giudici, D. and di Salle, E.: Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats. Prostate, 35: 237, 1998
23. Levy, M. A., Brandt, M., Sheedy, K. M., Dinh, J. T., Holt, D. A., Garrison, L. M. et al: Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. J Steroid Biochem Mol Biol, 48: 197, 1994
24. Lamb, J. C., Levy, M. A., Johnson, R. K. and Isaacs, J. T.: Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. Prostate, 21: 15, 1992
25. Kojo, H., Nakayama, O., Hirosumi, J., Chida, N., Notsu, Y. and Okuhara, M.: Novel steroid 5 alpha-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes. Mol Pharmacol, 48: 401, 1995
26. Esmat, A. Y., Refaie, F. M., Shaheen, M. H. and Said, M. M.: Chemoprevention of prostate carcinogenesis by DFMO and/or fmasteride treatment in male Wistar rats. Tumori, 88: 513, 2002
27. Tsukamoto, S., Akaza, H., Onozawa, M., Shirai, T. and Ideyama, Y.: A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer, 82: 531, 1998
28. Presti, J. C., Jr., Fair, W. R., Andriole, G., Sogani, P. C., Seidmon, E. J., Ferguson, D. et al: Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol, 148: 1201, 1992
29. Andriole, G., Lieber, M., Smith, J., Soloway, M., Schroeder, F., Kadmon, D. et al: Treatment with finasteride following radical prostatectomy for prostate cancer. Urology, 45: 491, 1995
30. Cote, R. J., Skinner, E. C., Slaem, C. E., Mertes, S. J., Stanczyk, F. Z., Henderson, B. E. et al: The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer, 78: 413, 1998
31. Bautista, O. M., Kusek, J. W., Nyberg, L. M., McConnell, J. D., Bain, R. P., Miller, G. et al: Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials, 24: 224, 2003
32. Andriole, G. L., Roehrborn, C., Schulman, C., Slawin, K. M., Sommerville, M. and Rittmaster, R. S.: Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology, 64: 537, 2004
33. Andriole, G. L., Guess, H. A., Epstein, J. I., Wise, H., Kadmon, D., Crawford, E. D. et al: Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology, 52: 195, 1998
34. Yang, X. J., Lecksell, K., Short, K., Gottesman, J., Peterson, L., Bannow, J. et al: Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology, 53: 696, 1999
35. Andriole, G. L., Bautista, O. M., Crawford, E. D., Kusek, J. W., McConnell, J. D., Lucia, S. et al: Prostate cancer (CAP) detection in the Medical Therapy of Prostatic Symptoms (MTOPS) trial. J Urol, 169: 120, 2003
36. Feigl, P., Blumenstein, B., Thompson, I., Crowley, J., Wolf, M., Kramer, B. S. et al: Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials, 16: 150, 1995
37. Scardino, P. T.: The prevention of prostate cancer-the dilemma continues. N Engl J Med, 349: 297, 2003
38. Marberger, M., Adolfsson, J., Borkowski, A., Fitzpatrick, J., Kirk, D., Prezioso, D. et al: The clinical implications of the prostate cancer prevention trial. BJU Int, 92: 667, 2003
39. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D. et al: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med, 327: 1185, 1992
40. Oesterling, J. E., Roy, J., Agha, A., Shown, T., Krarup, T., Johansen, T. et al: Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group. Urology, suppl., 51: 58, 1998
41. Marks, L. S., Partin, A. W., Dorey, F. J., Gormley, G. J., Epstein, J. I., Garris, J. B. et al: Long-term effects of finasteride on prostate tissue composition. Urology, 53: 574, 1999
42. Djavan, B., Zlotta, A. R., Ekane, S., Remzi, M., Kramer, G., Roumeguere, T. et al: Is one set of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol, 38: 218, 2000
43. Civantos, F., Watson, R. B., Pinto, J. E., Korman, R. B. and Soloway, M. S.: Finasteride effect on prostatic hyperplasia and prostate cancer: a comparative clinico-pathologic study of radical prostatectomies. J Urol Pathol, 6: 1, 1997
44. Montironi, R. and Diamanti, L.: Morphologic changes in benign prostatic hyperplasia following chronic treatment with a 5alpha-reductase inhibitor finasteride. Comparison with combination endocrine therapy. J Urol Pathol, 4: 123, 1996
45. Hochberg, D. A., Basillote, J. B., Armenakas, N. A., Vasovic, L., Shevchuk, M., Pareek, G. et al: Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol, 167: 1731, 2002
46. Glassman, D. T., Chon, J. K., Borkowski, A., Jacobs, S. C. and Kyprianou, N.: Combined effect of terazosin and finasteride on apoptosis, cell proliferation and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate, 46: 45, 2001
47. Montironi, R., Valli, M. and Fabris, G.: Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. J Clin Pathol, 49: 324, 1996
48. Ellison, E., Chuang, S. S. and Zincke, H.: Prostate adenocarcinoma after androgen deprivation therapy: a comparative study of morphology, morphometry, immunohistochemistry, and DNA ploidy. Pathol Case Rev, 2: 36, 1996
49. Ferguson, J., Zincke, H., Ellison, E., Bergstrahl, E. and Bostwick, D. G.: Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology, 44: 91, 1994
50. Bostwick, D. G.: Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Anat Pathol, 3: 1, 1998
51. Algaba, F., Epstein, J. I., Aldape, H. C., Farrow, G. M., Lopez-Beltran, A., Maksem, J. et al: Assessment of prostate carcinoma in core needle biopsy - definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer, 78: 376, 1996
52. Andriole, G., Bostwick, D., Brawley, O., Gomella, L., Marberger, M., Tindall, D. et al: Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol, 172: 1314, 2004